However, in a previous study, we showed an important part of these mechanisms in which we observed that FGF21 increased in response to CS treatment thereby reducing steatosis, inflammation, and fibrosis in the NASH animal model [17]. Here, FGF21 is linked to metabolic dysfunction-associated steatohepatitis.